Millions of people enrolled in Medicare Advantage, Medicaid, CHIP, and federal marketplace plans could see drug prior authorization decisions arrive days faster under a proposed federal rule now open for public comment until June 15, 2026. The Centers for Medicare & Medicaid Services (CMS) wants to require health plans to approve or deny standard drug prior authorization requests within 72 hours and urgent requests within 24 hours. The proposal would also mandate electronic prior authorization systems for prescription drugs and public reporting of approval, denial, and turnaround-time metrics.
What is verified so far
The proposed rule, designated CMS-0062-P, would extend electronic prior authorization and application programming interface (API) requirements to drugs for the first time. According to the CMS policy page for this proposal, the rule applies to Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care plans, and qualified health plan issuers on the federally facilitated marketplace. CMS is proposing shorter decision timeframes, new transparency obligations through public metrics reporting, and updated technical standards for how plans process drug authorization requests electronically.
CMS has framed the 72-hour standard window and 24-hour urgent window as a direct response to delays that keep patients waiting for needed medications. In its official announcement, the agency specifies that drug prior authorization decisions must be communicated no later than 24 hours for urgent requests and 72 hours for standard requests. The rule would also require plans to modernize their electronic systems, including use of standardized APIs, and to disclose how often they approve, deny, or partially approve prior authorization requests for prescription drugs.
This proposal builds on an earlier final rule, CMS-0057-F, which established similar interoperability and prior authorization requirements for non-drug items and services such as imaging, procedures, and durable medical equipment. That 2024 rule set a 72-hour expedited and 7-day standard timeframe for certain payers handling medical services. CMS-0062-P essentially mirrors that framework and applies it to prescription drugs, closing a gap that left many drug authorizations without the same speed and data-sharing requirements that now apply to other covered services.
Part D plans already operate under related deadlines in a narrower context. Existing regulations require written notice within 24 hours for expedited coverage determinations and within 72 hours for standard determinations, but those clocks generally start only after a prescriber submits all required documentation for an exception or formulary coverage request. The new proposal would apply comparable timeframes more broadly across drug prior authorization, not just to limited categories of exception requests, and would tie those timeframes to interoperable electronic workflows intended to reduce back-and-forth paperwork.
A CMS fact sheet indicates that affected payers would need to implement or upgrade APIs capable of handling prior authorization requests, responses, and status checks for drugs. Plans would be expected to support electronic exchange of clinical data needed to make coverage decisions, respond with clear reason codes when denying or modifying a request, and make aggregated prior authorization metrics publicly available in a machine-readable format. CMS contends that these changes will reduce administrative burden for clinicians and pharmacies while giving patients more predictable access to prescribed therapies.
What remains uncertain
CMS has not released public baseline data on current average decision times or denial rates for drug prior authorization under Medicare Advantage, Medicaid managed care, or marketplace plans. Without that benchmark, it is difficult to quantify how much faster the proposed 72-hour and 24-hour windows would be compared with current practice across different payers and benefit designs. The agency cites stakeholder complaints about delays and administrative burden, but the proposal does not include plan-level performance data that would allow outside observers to compare current and projected turnaround times.
It is also unclear how uniformly plans will be able to meet the new electronic requirements on the proposed implementation schedule. Many large insurers already use electronic prior authorization tools for at least some drugs, often in partnership with pharmacy benefit managers, but smaller plans and state Medicaid programs may rely more heavily on manual processes. The rule envisions standardized APIs and data formats, yet the extent of technical variation across vendors and legacy systems could affect how smoothly providers and pharmacies experience the transition.
Another open question is how the new transparency provisions will influence plan behavior. Public reporting of approval, denial, and partial approval rates could create reputational pressure on plans with comparatively high denial rates or slow response times. However, the proposal does not spell out exactly how patients, clinicians, or regulators might use those metrics in practice, nor does it specify whether CMS intends to incorporate the data into oversight activities, star ratings, or contract evaluations in future rulemaking.
Finally, the proposal does not resolve broader debates over the appropriate role of prior authorization in drug coverage. Even with faster decisions and electronic workflows, clinicians and patient advocates may continue to argue that some utilization management policies are clinically unnecessary or overly burdensome. Plans, for their part, are likely to emphasize the need to manage costs and promote evidence-based prescribing. How those competing priorities play out will depend in part on the comments CMS receives before the June 15, 2026 deadline and any revisions the agency makes before finalizing the rule.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
